165 related articles for article (PubMed ID: 23994440)
1. Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
Vo P; Jaffe ES; Cook L; Ramos C; Childs R
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e1-5. PubMed ID: 23994440
[No Abstract] [Full Text] [Related]
2. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Chang JE; Li H; Smith MR; Gascoyne RD; Paietta EM; Yang DT; Advani RH; Horning SJ; Kahl BS
Blood; 2014 Mar; 123(11):1665-73. PubMed ID: 24458437
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
5. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
Reddy N; Greer JP; Goodman S; Kassim A; Morgan DS; Chinratanalab W; Brandt S; Englehardt B; Oluwole O; Jagasia MH; Savani BN
Exp Hematol; 2012 May; 40(5):359-66. PubMed ID: 22269117
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
7. CCMCL1: a new model of aggressive mantle cell lymphoma.
Zhao X; Chen-Kiang S; Shetty S; Di Liberto M; Bodo J; Durkin L; Eng K; Elemento O; Smith MR; Hsi ED
Blood; 2015 Apr; 125(17):2730-2. PubMed ID: 25907904
[No Abstract] [Full Text] [Related]
8. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
10. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
Jacobsen E; Freedman A
Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
[TBL] [Abstract][Full Text] [Related]
11. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Tam CS; Bassett R; Ledesma C; Korbling M; Alousi A; Hosing C; Kebraei P; Harrell R; Rondon G; Giralt SA; Anderlini P; Popat U; Pro B; Samuels B; Hagemeister F; Medeiros LJ; Champlin RE; Khouri IF
Blood; 2009 Apr; 113(18):4144-52. PubMed ID: 19168784
[TBL] [Abstract][Full Text] [Related]
12. Role of allogeneic stem cell transplantation in mantle cell lymphoma.
Cohen JB; Burns LJ; Bachanova V
Eur J Haematol; 2015 Apr; 94(4):290-7. PubMed ID: 25154430
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
15. [Current treatment of follicular lymphoma].
Bonnet C; Beguin Y; Deprijck B; de Leval L; Fillet G
Rev Med Suisse; 2009 Aug; 5(214):1663-7. PubMed ID: 19772198
[TBL] [Abstract][Full Text] [Related]
16. Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Bakhous A; Zhu H; Waheed S
Br J Haematol; 2013 Nov; 163(3):293. PubMed ID: 23930696
[No Abstract] [Full Text] [Related]
17. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
19. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O;
Leukemia; 2015 Feb; 29(2):464-73. PubMed ID: 25034148
[TBL] [Abstract][Full Text] [Related]
20. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Houot R; Le Gouill S; Ojeda Uribe M; Mounier C; Courby S; Dartigeas C; Bouabdallah K; Alexis Vigier M; Moles MP; Tournilhac O; Arakelyan N; Rodon P; El Yamani A; Sutton L; Fornecker L; Assouline D; Harousseau JL; Maisonneuve H; Caulet-Maugendre S; Gressin R;
Ann Oncol; 2012 Jun; 23(6):1555-61. PubMed ID: 22012966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
